DeepMed Research

Bioverativ Therapeutics Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Biological: rFVIIIFc

First Posted Date: 2015-07-20

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 24

Registration Number: NCT02502149

Locations: 🇳🇿
Research Site, Hamilton, New Zealand

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

Completed

Conditions: Healthy
Sickle Cell Disease

First Posted Date: 2015-05-19

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 38

Registration Number: NCT02447627

Locations: 🇺🇸
Research Site, Detroit, Michigan, United States

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

Terminated

Conditions: Hemophilia A
Hemophilia B

Interventions: Biological: rFVIIIFc
Biological: rFIXFc
Drug: non-Fc FVIII replacement products
Drug: non-Fc FIX replacement products

First Posted Date: 2015-03-18

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 3

Registration Number: NCT02392156

Locations: 🇺🇸
Research Site, East Lansing, Michigan, United States

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Phase 1

Completed

Conditions: Severe Hemophilia A

Interventions: Biological: rFVIIIFc

First Posted Date: 2014-03-11

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 19

Registration Number: NCT02083965

Locations: 🇬🇧
Research Site, London, United Kingdom

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Drug: BIIB031 (rFVIIIFc)
Drug: FVIII (PK subgroup only)

First Posted Date: 2011-10-24

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 71

Registration Number: NCT01458106

Locations: 🇬🇧
Research Site, London, United Kingdom

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Drug: rFVIIIFc

First Posted Date: 2011-10-19

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 240

Registration Number: NCT01454739

Locations: 🇬🇧
Research Site, London, United Kingdom
🇳🇿
Research site, Wellington, New Zealand
🇭🇰
Children Cancer Centre, Hong Kong, New Territories, Hong Kong

and more 1 locations

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

Phase 3

Completed

Conditions: Hemophilia B

Interventions: Drug: rFIXFc
Drug: FIX

First Posted Date: 2011-09-27

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 30

Registration Number: NCT01440946

Locations: 🇬🇧
Research Site, London, United Kingdom

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

Phase 3

Completed

Conditions: Severe Hemophilia B

Interventions: Biological: rFIXFc

First Posted Date: 2011-08-30

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 120

Registration Number: NCT01425723

Locations: 🇬🇧
Research Site, Basingstoke, Hampshire, United Kingdom
🇬🇧
Research site, London, Greater London, United Kingdom

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Drug: Factor VIII (rFVIIIFc)
Drug: Advate®

First Posted Date: 2010-08-13

Last Posted Date: 2021-01-08

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 165

Registration Number: NCT01181128

Locations: 🇬🇧
Research Site, London, United Kingdom

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Phase 1

Completed

Conditions: Severe Hemophilia A

Interventions: Drug: rFVIIIFc

First Posted Date: 2009-12-07

Last Posted Date: 2020-12-19

Lead Sponsor: Bioverativ Therapeutics Inc.

Target Recruit Count: 16

Registration Number: NCT01027377

Locations: 🇮🇱
Research Site, Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy